Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 16/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5437256 | 0.88 | GRM2 (0.67) | GRM2 | |
| SCHEMBL5442689 | 0.84 | KDM4E (0.50) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5433914 | 0.81 | GRM2 (0.49) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5437313 | 0.80 | KDM4E (0.54) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5448940 | 0.79 | KDM4E (0.64) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5435558 | 0.78 | KDM4E (0.68) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5444894 | 0.77 | KDM4E (0.40) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5443023 | 0.76 | GRM2 (0.47) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5437231 | 0.76 | GRM2 (0.49) | GRM2KDM4EALDH1A1MAPK1PIM1 | |
| SCHEMBL5448963 | 0.75 | ALDH1A1 (0.44) | GRM2KDM4EALDH1A1MAPK1PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101061098-B | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV | 2012-05-23 | — | — | CN | claimed |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | ADDEX PHARMACEUTICALS S.A. (CH) | 2013-05-02 | — | — | US | disclosed |
| US-8399493-B2 | Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors | Janssen Pharmaceuticals, Inc. (US) | 2013-03-19 | — | — | US | disclosed |
| CN-101061098-B | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV | 2012-05-23 | — | — | CN | disclosed |
| CN-101061098-A | Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-24 | — | — | CN | disclosed |
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | Janssen Pharmaceuticals, Inc. | 2007-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213323-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRM3 | GRM2 1/4885KDM4E 1936/4885ALDH1A1 3403/4885 |
| US-20130109652-A1 | NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS | GRM2, GRM1, GRIA2 | GRM2 1/4885KDM4E 1707/4885ALDH1A1 2717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.